U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07595172) titled 'NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer' on April 09.
Brief Summary: This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Ductal Adenocarcinoma (PDAC)
Locally Advanced and Metastatic Pancreatic Cancer
Intervention:
DRUG: NALIRIFOX+Adebrelimab
NALIRIFOX chemotherapy and Adebrel...